Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-09-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于向特定对象发行股票申请文件修订说明的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding revisions to the application documents for a specific share issuance to targeted investors. It details updates to the prospectus and related application materials for a private placement of A-shares, including clinical progress updates and other adjustments. The document is short (1318 characters) and serves as a notice about changes to the issuance application documents rather than the issuance documents themselves or a full financial report. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising activities and capital structure changes.
2021-09-14 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a 2021 private placement of A shares by Beijing Sinocelltech Group Co., Ltd. It is issued by CITIC Securities as the sponsor and underwriter. The content includes detailed information about the issuer, shareholding structure, issuance background, financial data, and regulatory compliance references. The document is a formal sponsorship letter for a securities issuance, which is a type of capital raising activity. It is not an annual report, earnings release, or management discussion, nor is it a voting result or proxy statement. It is a detailed document related to a capital/financing update, specifically a private placement issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-09-14 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) related to a specific issuance of A shares by Beijing Sinocelltech Group Limited for the year 2021. It includes extensive company background, business description, core technologies, R&D status, financial data, and detailed risk disclosures related to the issuance and the company's operations. The document references regulatory frameworks and securities laws relevant to stock issuance and listing on the Shanghai Stock Exchange's STAR Market (科创板). It is not a typical annual report or earnings release but rather a formal regulatory filing associated with a capital raising event (stock issuance). The document is lengthy (15,000 characters) and contains substantive financial and business information related to the issuance. Given the focus on the issuance of shares to specific investors and the detailed description of the offering, this document fits best under the category of Capital/Financing Update (CAP).
2021-09-14 Chinese
北京神州细胞生物技术集团股份公司截至2021年6月30日止前次募集资金使用情况报告及鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况报告及鉴证报告" which translates to "Previous Fundraising Usage Report and Assurance Report." It includes detailed information about the use of funds raised in a previous equity issuance, with specific dates (up to June 30, 2021), amounts raised, usage details, and an assurance report by an accounting firm (PwC). The document is a standalone audit/assurance report on the use of previously raised capital, not a full annual or interim financial report. It does not contain general financial statements or management discussion but focuses on verifying the use of fundraising proceeds. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/assurance report related to the use of funds raised, including the auditor's opinion and verification procedures. The document length (over 10,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. H1 2021
2021-09-10 Chinese
神州细胞2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2021 second extraordinary general meeting of shareholders. It includes details about the meeting date, attendance, voting results, and legal witness statements. There is no financial data or report content, only the official voting results and procedural compliance information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2021-09-10 Chinese
神州细胞前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is titled as a report on the usage of previously raised funds by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the amount of funds raised, their allocation, actual usage, and cash management activities related to the raised funds. It references official approvals from the China Securities Regulatory Commission and includes verification reports from PwC. The document is comprehensive and contains detailed financial figures and explanations about the use of the capital raised in a prior fundraising event. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a simple announcement or a certification but a detailed report on the use of raised capital funds. Therefore, the appropriate classification is CAP with high confidence.
2021-09-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.